SCHEMBL1833211

SCHEMBL1833211

Oc1ccc(OCCc2ccccc2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.68
CYP1A2 P05177 1/20 0.68
PTGS1 P23219 1/20 0.68
SLC6A2 P23975 1/20 0.68
CYP2C19 P33261 1/20 0.68
PTGS2 P35354 1/20 0.68
SLC6A3 Q01959 1/20 0.68
HIF1A Q16665 1/20 0.68
HDAC6 Q9UBN7 1/20 0.68
NPC1 O15118 1/20 0.67
RAB9A P51151 1/20 0.67
FFAR1 O14842 3/20 0.64
DRD4 P21917 2/20 0.62
LTA4H P09960 1/20 0.57
CA12 O43570 1/20 0.57
CA1 P00915 1/20 0.57
CA2 P00918 1/20 0.57
CA7 P43166 1/20 0.57
CA9 Q16790 1/20 0.57
DRD2 P14416 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9374564 0.92 FFAR1 (0.59) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL1837433 0.90 LMNA (0.66) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL27624350 0.90 ESR1 (0.56) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL9456979 0.89 NPC1 (0.80) NPC1RAB9AFFAR1DRD4LTA4H
SCHEMBL10792214 0.89 LMNA (0.59) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL1837149 0.89 FFAR1 (0.66) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL8760892 0.87 ALDH1A1 (0.56) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL10904942 0.87 CA12 (0.66) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL1836368 0.87 FFAR1 (0.64) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL2091234 0.87 FFAR1 (0.64) LMNACYP1A2PTGS1SLC6A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6407071-B1 REMOVAL CYSTEINE FROM TUMOR CELL CO-ENZYME TECHNOLOGY LTD. 2002-06-18 US claimed
US-5760008-A Method and compositions for treating malignant tumors and inhibiting metastases of malignant tumors CO ENZYME TECHNOLOGY LTD. (US) 1998-06-02 US claimed
US-5639737-A Method and compositions for treating malignant tumors and inhibiting growth and metastases of malignant tumors CO ENZYME TECHNOLOGY LTD. (US) 1997-06-17 US claimed
US-5476842-A Method and compositions for treating tumors having high tyrosinase activity CO ENZYME TECHNOLOGY LTD. (US) 1995-12-19 US claimed
US-5340803-A Method and compositions for treating tumors having high tyrosinase activity CO ENZYME TECHNOLOGY LTD. (US) 1994-08-23 US claimed
US-4952661-A AND DICARBOXYLIC AROMATIC ACID, AND OPTIONALLY A HYDROQUINONE; ANISOTROPIC MONTEDISON S.P.A. (IT) 1990-08-28 US claimed
EP-0300752-A2 Thermotropic liquid crystalline polyesters Montedison S.p.A. (IT) 1989-01-25 EP claimed
US-20240425448-A1 METHOD FOR PRODUCING ISOCYANATE COMPOUND, METHOD FOR PRODUCING CARBAMATE COMPOUND, METHOD FOR RECOVERING AMINE COMPOUND, AND ISOCYANATE COMPOSITION ASAHI KASEI KABUSHIKI KAISHA (JP) 2024-12-26 US disclosed
EP-4431490-A1 METHOD FOR PRODUCING ISOCYANATE COMPOUNDS, METHOD FOR PRODUCING CARBAMATE COMPOUNDS, METHOD FOR RECOVERING AMINE COMPOUNDS, AND ISOCYANATE COMPOSITION Asahi Kasei Kabushiki Kaisha (JP) 2024-09-18 EP disclosed
CN-118215651-A Method for producing isocyanate compound, method for producing urethane compound, method for recovering amine compound, and isocyanate composition 旭化成株式会社 2024-06-18 CN disclosed
WO-2023080257-A1 METHOD FOR PRODUCING ISOCYANATE COMPOUNDS, METHOD FOR PRODUCING CARBAMATE COMPOUNDS, METHOD FOR RECOVERING AMINE COMPOUNDS, AND ISOCYANATE COMPOSITION 旭化成株式会社 2023-05-11 WO disclosed
US-20230002679-A1 COMPOUND AND LIQUID CRYSTAL COMPOSITION FUJIFILM CORPORATION (JP) 2023-01-05 US disclosed
EP-3416612-B1 FRAGRANT MIXTURES CONTAINING ESTERS AND KETONES SYMRISE AG (DE) 2022-12-28 EP disclosed
EP-0573080-A1 Dye-donor element for use according to thermal dye sublimation transfer AGFA-GEVAERT N.V. (BE) 1993-12-08 EP disclosed
EP-0531580-A1 Dye-donor element for use according to thermal dye sublimation transfer AGFA-GEVAERT N.V. (BE) 1993-03-17 EP disclosed
EP-0531579-A1 Dye-image receiving element for use according to thermal dye sublimation transfer AGFA-GEVAERT N.V. (BE) 1993-03-17 EP disclosed
US-4952661-A AND DICARBOXYLIC AROMATIC ACID, AND OPTIONALLY A HYDROQUINONE; ANISOTROPIC MONTEDISON S.P.A. (IT) 1990-08-28 US disclosed
EP-0300752-A2 Thermotropic liquid crystalline polyesters Montedison S.p.A. (IT) 1989-01-25 EP disclosed
US-4538164-A LEUCO DYE, HYDROXYPHENOLIC ETHER DEVELOPER, OIL ABSORBING FILLER RICOH CO., LTD. (JP) 1985-08-27 US disclosed
US-3980678-A Anthraquinone disperse dyes SUMITOMO CHEMICAL COMPANY, LIMITED (JA) 1976-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240425448-A1 METHOD FOR PRODUCING ISOCYANATE COMPOUND, METHOD FOR PRODUCING CARBAMATE COMPOUND, METHOD FOR RECOVERING AMINE COMPOUND, AND ISOCYANATE COMPOSITION IDH3A, CA7, C9 LMNA 1675/4885CYP1A2 297/4885PTGS1 1886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.